Medicine Matters rheumatology

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

Learn more

Have the ORAL Surveillance results changed rheumatology practice?

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

New additions to the Adis Journal Club – August update

Browse August's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

News

TNF inhibitor use during pregnancy linked to higher infant birthweight

Tumor necrosis factor inhibitor use by pregnant women with well-controlled rheumatoid arthritis is associated with a reduced risk for having a child that is born small for gestational age, study findings indicate.

Support for long-term use of biologics in people with HIV

Gout flares linked to temporary increase in cardiovascular risk

Sequential rituximab, mepolizumab regimen may warrant further investigation for EGPA

Voclosporin set for EMA approval for lupus nephritis

FDA approves belimumab for pediatric lupus nephritis

Benefits of risk stratification for musculoskeletal pain questioned

View all latest news

IN FOCUS | JAK inhibitors

05-08-2022 | JAK inhibitors | Video

Have the ORAL Surveillance results changed rheumatology practice?

EMA recommends approval of upadacitinib for nonradiographic axSpA

Targeted therapy not linked to serious infection risk in older people with RA

Call for CV risk assessment when starting tofacitinib in patients with PsA

Deucravacitinib warrants further investigation for SLE

Mixed results for MACE risk with JAK inhibitors in RA

Evidence for baricitinib efficacy in SLE ‘remains inconclusive’

IN FOCUS | COVID-19 & rheumatic disease

30-06-2022 | COVID-19 | News

VROOM trial: Pausing methotrexate doubles antibody response to COVID-19 booster vaccine

Holding methotrexate treatment for 2 weeks following administration of a booster dose of vaccines against SARS-CoV-2 significantly improves the humoral immune response to vaccination, suggest findings from a randomized controlled trial.

IN FOCUS | Inflammatory arthritis

28-07-2022 | Rheumatoid arthritis | News

TNF inhibitor use during pregnancy linked to higher infant birthweight

Support for long-term use of biologics in people with HIV

Gout flares linked to temporary increase in cardiovascular risk

TNF inhibitor use during pregnancy linked to higher infant birthweight

NICE recommends guselkumab for broader PsA population

Bimekizumab demonstrates sustained benefits in PsA, ankylosing spondylitis

Study highlights sex-specific CVD risks in men with gout

IN FOCUS | Gout and crystal arthropathies

25-01-2022 | Gout | News

Allopurinol use not linked to increased mortality risk in people with gout, CKD

Individuals with gout and concurrent chronic kidney disease are no more likely to die following allopurinol initiation, dose escalation, or achievement of target serum urate levels than those not taking the drug, study findings indicate.

Gout flares linked to temporary increase in cardiovascular risk

Study highlights sex-specific CVD risks in men with gout

Topical alkalinizing treatment shows potential for acute gout

Methotrexate add-on therapy boosts pegloticase efficacy in refractory gout

Support for gout self-management for improving urate levels

Colchicine prophylaxis associated with ‘markedly reduced’ gout flare risk after COVID-19 vaccination

IN FOCUS | Lupus

17-05-2022 | Systemic lupus erythematosus | News

Vascular plaque burden could predict future CVD risk in people with SLE

The overall burden of vascular plaque measured on ultrasound scans is significantly associated with future risk for cardiovascular disease events in people with systemic lupus erythematosus, study findings indicate.

Voclosporin set for EMA approval for lupus nephritis

FDA approves belimumab for pediatric lupus nephritis

Leflunomide shows promise in lupus nephritis

LOTUS trial suggests no benefit of ustekinumab in SLE

Maintenance therapy discontinuation may be risky in proliferative lupus nephritis

Predictors of complete remission in SLE identified

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Image Credits

Medicine Matters branded image/© Springer Healthcare, Richard Conway and Kevin Winthrop, Rheumatology & Therapy, Mid section of pregnant woman standing in corridor of hospital (symbolic image with model)/© Wavebreakmedia / Getty Images / iStock, Adis Journal Club, Magnifying glass and laptop/© Michail_Petrov-96 / Getty Images / iStock, Antibodies, immunoglobulin proteins, Immune system. 3D rendering/© Gilnature / Getty Images / iStock, Covid-19 vaccine vial and needle close up/© Leigh Prather / stock.adobe.com, Vector illustration of two profiles with speech bubbles inside their heads - debate concept/© JakeOlimb / Getty Images / iStock, Covid-19 vaccine concept/© shintartanya / stock.adobe.com, IV drip/© © Trsakaoe / stock.adobe.com, Antibodies (illustration)/© Svisio/Getty Images, Doctor and calculator/© nito / stock.adobe.com, Kidneys/© psdesign1 / fotolia.com , Febuxostat and CV risk signpost image/© hriana / stock.adobe.com, Coronary artery plaque/© 7activestudio / stock.adobe.com, Anifrolumab for the treatment of lupus/© ustas / stock.adobe.com, New Content Item/© bloomicon / stock.adobe.com